Uses of Wegovy

Wegovy is a subcutaneous injection, with the main ingredient Semaglutide, commonly used as an adjunct to a reduced-calorie diet and increased physical activity for weight control in adults who are overweight or fat. Knowing the basic information about Wegovy's ingredients, uses, dosages and side effects will help patients improve treatment effectiveness.

Wegovy drug is prepared in the form of a solution in an injection pen, containing the main ingredients including:
Active ingredients: Semaglutide content of 0.25 mg, 0.5 mg, 1 mg in 0.5 ml of solution. Semaglutide content 1.7 mg, 2.4 mg in 0.75 ml solution. Excipients: Disodium phosphate dihydrate, Sodium chloride, Hydrochloric acid, Sodium hydroxide, water for injection. GLP-1 is a physiological regulator of appetite and calorie intake, and GLP-1 receptors are present in several areas of the brain involved in appetite regulation. The active ingredient Semaglutide in Wegovy is a GLP-1 analogue with 94% structural homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds and activates the GLP-1 receptor, helping to reduce appetite and downregulate the body's calorie intake. In addition, Semaglutide also stimulates insulin secretion and reduces Glucagon secretion dependent on glucose, which in turn may lead to a decrease in blood glucose levels.

Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight control in adults whose baseline body mass index (BMI) is:
Obesity: BMI ≥ 30 kg/m2. Overweight: BMI ≥ 27 kg/m2 with at least one weight-related comorbidity such as: Hypertension; Type 2 diabetes ; Blood lipid disorders.

Hypersensitivity to any component of the drug Wegovy. History of allergy to other medicines containing the active ingredient Semaglutide. Patients with a personal or family history of medullary thyroid carcinoma (MTC). The patient has a personal or family history of multiple endocrine neoplasia Type 2 (Endocrine Neoplasia syndrome type 2 – MEN2).

Instructions for use of the drug
The dose of Wegovy is prescribed based on BMI. BMI is calculated by dividing weight (in kilograms - kg) by height (in meters - m) squared. Before using Wegovy injection, patients must be instructed by medical staff on proper injection technique, not to buy drugs to use on their own. Inject Wegovy under the skin in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without any dose adjustment. Dosage:
Initial dose: Subcutaneous injection 0.25 mg/time x 1 time/week. Increase dose:

Recommendation:
If the patient does not tolerate a dose during dose escalation, consider delaying the increase for 4 weeks. The maintenance dose of Wegovy is 2.4 mg subcutaneously once a week. If the patient is intolerant to the maintenance dose of 2.4 mg once a week, the dose may be temporarily reduced to 1.7 mg once a week for a maximum of 4 weeks. After 4 weeks, increase the Wegovy dose to a maintenance level of 2.4 mg once weekly. Discontinue Wegovy if the patient cannot tolerate the 2.4 mg dose.

Treatment with Wegovy drug with high dose or prolonged, may cause side effects such as:
Nervous: Headache, migraine, dizziness, dizziness, fatigue. Gastrointestinal: Gastrointestinal disorders nausea, vomiting and diarrhea, dyspepsia, abdominal pain, abdominal distension, dyspepsia, flatulence, gastroesophageal reflux disease, gastritis and hemorrhoids. Acute gallbladder disease, acute pancreatitis, appendicitis. Biochemistry: Increase Amylase and Lipase, lower blood glucose. Kidney: Acute kidney injury, dehydration. Cardiovascular: Increased heart rate, hypotension, orthostatic hypotension, syncope. Injection site reactions: Injection site itching, erythema, inflammation, induration and irritation. Body as a whole: Anaphylactic shock. Other: Hair loss, retinal disorders. When detecting the above undesirable effects or any other abnormalities after taking Wegovy, patients and relatives should promptly inform their doctor or pharmacist about the use of Wegovy or go to a medical facility immediately. for timely treatment.
Note the use of Wegovy in the following subjects:
Use caution when using Wegovy in the elderly, people with a history of or are suffering from acute pancreatitis, acute gallbladder disease, hypoglycemia, lesions Acute renal failure, complications of diabetic retinopathy in patients with type 2 diabetes, increased heart rate irregularities, behavior and suicidal ideation. Pregnant women: Appropriate weight gain is now recommended for all pregnant patients, weight loss not only does not benefit the pregnant patient but may also harm the fetus. Therefore, caution should be exercised when using Wegovy in this population. Lactation: There are no data on the presence of Semaglutide in Wegovy in breast milk, affecting the nursing infant. However, the developmental and health benefits of breastfeeding need to be considered alongside the mother's clinical need for Wegovy. Drivers or machine operators often experience side effects such as headache, dizziness, dizziness... after using Wegovy.

Interactions with other drugs:
The risk of hypoglycemia is increased when Wegovy is used in combination with insulin secretagogues such as Sulfonylureas or Synthetic Insulin. Wegovy causes delayed gastric emptying and thus has the potential to affect the absorption of concomitant oral medications. Above is basic information about ingredients, uses, doses and precautions when using Wegovy. In order to bring about the best treatment effect, patients should carefully read the instructions for using Wegovy, and strictly follow the doctor's instructions.